Vaxcyte, Inc. PCVX Software and Technology Licenses, Net
Software and Technology Licenses, Net at other companies
Other financials
Where this comes from
Reported directly by Vaxcyte, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vaxcyte, Inc.'s software and technology licenses, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vaxcyte, Inc.'s software and technology licenses, net?
- Vaxcyte, Inc. (PCVX) reported software and technology licenses, net of $155.54M in Q1 2026.
- How has Vaxcyte, Inc.'s software and technology licenses, net changed year-over-year?
- Vaxcyte, Inc.'s software and technology licenses, net increased by 103.9% year-over-year, from $76.28M to $155.54M.
- What is the long-term trend for Vaxcyte, Inc.'s software and technology licenses, net?
- Over 5 years (2020 to 2025), Vaxcyte, Inc.'s software and technology licenses, net has grown at a 193.0% compound annual growth rate (CAGR), from $550K to $118.85M.